In established RA patients from the ARMADA trial, the lowest P value comparing ADA+MTX versus PBO+MTX at week 24 was observed at CDAI 45%, while the greatest difference was observed at CDAI 60% (Fig. 2d and Additional file 1: Table S1). Here, ADA is linked to rheumatoid arthritis.